Education
About Us
Working with TipRanks
Follow Us
WuXi XDC Cayman, Inc. (HK:2268)
:2268
2268 Stock Chart & Stats
HK$65.50
HK$1.55(5.24%)
At close: 4:00 PM EST
HK$65.50
HK$1.55(5.24%)
Day’s Range― - ―
52-Week RangeHK$24.70 - HK$85.50
Previous CloseN/A
Volume4.11M
Average Volume (3M)6.66M
Market Cap
HK$81.77B
Enterprise ValueHK$72.89B
Total Cash (Recent Filing)HK$4.54B
Total Debt (Recent Filing)HK$1.04B
Price to Earnings (P/E)54.5
Beta1.05
Next Earnings
Mar 23, 2026EPS Estimate
0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding1,257,992,700
10 Day Avg. Volume10,688,598
30 Day Avg. Volume6,656,062
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.20
Price to Sales (P/S)8.51
P/FCF Ratio-43.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$85.28Price Target Upside30.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA 90.8% revenue increase indicates rapidly expanding demand for WuXi XDC's CDMO services and successful client wins. Sustained high topline growth supports scale advantages, amortization of fixed costs, reinvestment in capacity and R&D, and strengthens long-term competitive positioning.
Robust Profitability MarginsHigh gross, EBIT and net margins reflect meaningful pricing power and operational efficiency in contract development and manufacturing. Durable margins provide internal cash to fund expansion, absorb pricing pressure, and sustain returns to shareholders even through moderate demand cycles.
Low Leverage & Strong Equity BaseVery low leverage and a high equity ratio give significant financial flexibility to fund capex, pursue partnerships, and withstand industry cyclicality. A 16.1% ROE shows effective capital use, supporting long-term investment capacity without straining solvency.
Bears Say
Negative Free Cash FlowLarge negative free cash flow driven by heavy capex reduces unencumbered liquidity and may force reliance on external financing. If sustained, this constrains dividend or buyback capacity and increases execution risk if revenue growth or margin levels decelerate.
Free Cash Flow To Net Income NegativeA negative free cash flow to net income ratio signals earnings are not translating into discretionary cash, limiting internal funding for growth. Persisting negative conversion elevates refinancing risk and can impair strategic flexibility over a multi-quarter horizon.
Sub-1 Operating Cash ConversionOperating cash converts at only ~67% of net income, leaving a meaningful portion of profits tied in working capital or non-cash items. With high capex needs, this lower conversion rate may pressure liquidity and require tighter working-capital management to sustain growth.
WuXi XDC Cayman, Inc. News
2268 FAQ
What was WuXi XDC Cayman, Inc.’s price range in the past 12 months?
WuXi XDC Cayman, Inc. lowest stock price was HK$24.70 and its highest was HK$85.50 in the past 12 months.
What is WuXi XDC Cayman, Inc.’s market cap?
WuXi XDC Cayman, Inc.’s market cap is HK$81.77B.
When is WuXi XDC Cayman, Inc.’s upcoming earnings report date?
WuXi XDC Cayman, Inc.’s upcoming earnings report date is Mar 23, 2026 which is in 28 days.
How were WuXi XDC Cayman, Inc.’s earnings last quarter?
WuXi XDC Cayman, Inc. released its earnings results on Aug 18, 2025. The company reported HK$0.642 earnings per share for the quarter, missing the consensus estimate of HK$0.687 by -HK$0.045.
Is WuXi XDC Cayman, Inc. overvalued?
According to Wall Street analysts WuXi XDC Cayman, Inc.’s price is currently Undervalued.
Does WuXi XDC Cayman, Inc. pay dividends?
WuXi XDC Cayman, Inc. does not currently pay dividends.
What is WuXi XDC Cayman, Inc.’s EPS estimate?
WuXi XDC Cayman, Inc.’s EPS estimate is 0.7.
How many shares outstanding does WuXi XDC Cayman, Inc. have?
WuXi XDC Cayman, Inc. has 1,257,992,700 shares outstanding.
What happened to WuXi XDC Cayman, Inc.’s price movement after its last earnings report?
WuXi XDC Cayman, Inc. reported an EPS of HK$0.642 in its last earnings report, missing expectations of HK$0.687. Following the earnings report the stock price went down -1.124%.
Which hedge fund is a major shareholder of WuXi XDC Cayman, Inc.?
Currently, no hedge funds are holding shares in HK:2268
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi XDC Cayman, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.79%
12-Months-Change
Fundamentals
Return on Equity
19.62%
Trailing 12-Months
Asset Growth
48.98%
Trailing 12-Months
Company Description
WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
2268 Stock 12 Month Forecast
Average Price Target
HK$85.28
▲(30.20% Upside)
Technical Analysis
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---